Navigation Links
Chiasma Grants Option to License Transient Permeability Enhancer (TPE) Technology for Small Molecule Products
Date:1/19/2010

JERUSALEM, Jan. 19 /PRNewswire/ -- Chiasma, Inc., a privately held biopharma company, announced today that it has granted Novartis an option to obtain exclusive worldwide rights to develop and commercialize the Company's Transient Permeability Enhancer (TPE) technology for use with certain related small molecule products either in development or currently marketed by Novartis. In a separate but related agreement, the MPM Bio IV NVS Strategic Fund L.P. made an equity investment in Chiasma.

The two companies have initiated a feasibility program funded by Novartis. Should Novartis exercise the option, it would assume the global clinical development, manufacturing, regulatory submissions and commercialization of the products containing the TPE technology. Chiasma would receive payments upon the option exercise and upon successful completion of certain development and regulatory milestones. In addition, Chiasma would be eligible to receive a percentage of any incremental profits generated as a result of the incorporation of the TPE technology into these Novartis products. Additional terms were not disclosed.

Fredric Price, Chairman and CEO of Chiasma said, "Our strategy is two-fold: (1) to develop our own proprietary products and seek out partnerships after demonstrating clinical effectiveness and safety; and (2) to enter into arrangements with companies whose important drugs could benefit from the TPE technology.

"Our internally-developed pipeline is focused on developing new therapies by selecting approved macromolecules that are currently available in injectable form, changing the route of administration to oral and evaluating them for new indications, thereby creating new drugs that will take advantage of the 505(b)(2) regulatory route in the US and similar regulations in other countries.

"We are especially pleased that our first collaboration is with an important marketed product from Novartis, along with certain other products in development in the same area of therapy."

Todd Foley, Managing Director at MPM Capital commented, "In preclinical models, the TPE system has demonstrated encouraging efficacy results as measured by significant improvements in bioavailability when administered orally across a wide range of compounds that are currently available only by injection, and has also established a clean safety profile, which makes this an attractive investment opportunity."

About Chiasma

Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption.  The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver.  It is applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed.

The Company has successfully demonstrated proof-of-principle in delivering small proteins, peptides, saccharides and heretofore insoluble small molecules via the oral route.

Chiasma is backed by MPM Capital, ARCH Venture Partners, F2 Ventures, 7 Health Ventures and MPM Bio IV NVS Strategic Fund.

The Company's Chairman & CEO is Fredric Price, formerly Chairman of Omrix Biopharmaceuticals, Chairman & CEO of BioMarin Pharmaceutical and currently also Chairman of Peptimmune as well as a member of the boards of Pharmasset and Enobia Pharma; he is located in New York. The company's Chief Operating Officer is Roni Mamluk, PhD, formerly head of preclinical at Adnexus Therapeutics. She led the discovery of TPE technology and currently is heading operating departments (research, development, regulatory, manufacturing, intellectual property and human resources) in the Company's new facilities (including laboratories and GMP pilot plant) in Jerusalem.

Additional information can we found at: www.ChiasmaPharma.com.

SOURCE Chiasma, Inc.

RELATED LINKS
http://www.ChiasmaPharma.com

'/>"/>

SOURCE Chiasma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
2. European Medicines Agency Grants Cell Therapeutics Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL)
3. Pfenex Grants Exclusive License to Merck & Co., Inc. for the Production of Proteins for Undisclosed Vaccine Program
4. FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology
5. SRI International Receives National Institutes of Health Grants to Develop Improved Tomographic Imaging Technology
6. The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies
7. U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine)
8. FDA Grants GeoVax Labs, Inc. Request For Pre-IND Meeting
9. Ganeden Biotech Announces Grants for Early Investigators to Research Probiotic GanedenBC30
10. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
11. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
Breaking Medicine News(10 mins):